Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Glucagon

Pancreatic Alpha-Cell Hormone

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

Glucagon is an FDA-approved biologic with decades of clinical use for its labeled indications, so grade 5 is warranted for the approved uses rather than any broader metabolic halo. For severe hypoglycemia it is a first-line rescue therapy carried in the ADA Standards of Care, which recommend prescribing glucagon to all individuals on insulin or at high risk and note that ready-to-use forms not requiring reconstitution are preferred. Modern devices with pivotal trial support include Baqsimi nasal powder (FDA 2019) and Gvoke room-temperature liquid glucagon by prefilled syringe or auto-injector (FDA 2019); glucagon is also FDA-labeled as a diagnostic aid to temporarily inhibit gastrointestinal motility during radiologic and endoscopic procedures.

FDA
FDA Approved (emergency hypoglycemia)
WADA
Not prohibited (not listed on WADA Prohibited List)

Reference only. Not medical advice.

What can go wrong

Minimal in approved acute use; transient nausea/vomiting common, rebound or transient hyperglycemia with overdose, and it is ineffective when hepatic glycogen is depleted.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Glucagon. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

Insulin's counter-regulatory hormone, FDA-approved for emergency hypoglycemia and the basis for the dual/triple agonist drug classes (tirzepatide, retatrutide).

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Emergency hypoglycemia (approved)
  • Research target for combination agonists
Severe hypoglycemia rescue
The approved emergency use: glucagon rapidly raises blood sugar when a person with diabetes becomes severely hypoglycemic and cannot take sugar by mouth, available as injection kits, a nasal spray, ready-to-use autoinjectors and a next-generation analog.
Procedural and diagnostic use
Used to relax the gastrointestinal tract for certain imaging and endoscopic procedures.

How it works

Glucagon is insulin’s counterpart: a pancreatic hormone that raises blood sugar by telling the liver to release stored glucose. As a medicine it is best known as the emergency treatment for severe low blood sugar, and its receptor is now also being deliberately harnessed for weight loss in the newest triple-agonist drugs.

Glucagon is a 29-amino-acid peptide hormone made by the alpha cells of the pancreas, the counterpart to insulin from the neighboring beta cells. The two hormones work in opposition to keep blood sugar in range. It is given by injection or, more recently, as a needle-free nasal spray.

Type
Counter-regulatory hormone
Action
Raises blood sugar
Use
Hypoglycemia rescue
Onset
About 15 minutes
Forms
Injection, nasal
Approved
Yes

Insulin’s Mirror Image, And An Emergency Rescue

Glucagon is one half of the body’s blood-sugar thermostat, the hormone that pushes glucose up when insulin has pushed it too far down, and that makes it a genuine lifesaver in diabetes. Too much insulin can drop blood sugar to the point of seizure, coma or death, and when the person cannot eat or drink sugar, glucagon is the rescue that brings it back, usually within about fifteen minutes. For decades the catch was not the hormone but the delivery: the old emergency kits required mixing a powder and a liquid and drawing up an injection, a fiddly multistep process that frightened caregivers often got wrong in a crisis. That changed recently. Ready-to-use products arrived, a needle-free nasal powder, prefilled autoinjectors and a stable next-generation analog, all of which a panicking bystander can administer far faster and more reliably. The science here is settled; the real advance has been making the rescue usable. The same glucagon receptor is now also part of the newest obesity drugs, whose glucagon arm helps burn energy.

Safety in detail

Glucagon rescue depends on adequate liver glycogen and may not work in states of glycogen depletion such as prolonged fasting, starvation, chronic hypoglycemia, or adrenal insufficiency. Nausea and vomiting are the most common effects. Modern ready-to-use forms (Baqsimi nasal powder, Gvoke liquid) remove the error-prone reconstitution step of older emergency kits, which the ADA notes as preferred.

  • For emergency use it is very safe short-term; nausea and vomiting are the main effects.
  • Because it raises blood sugar, it is used to counter, not cause, metabolic problems in the rescue setting.
  • Its therapeutic use as a weight-loss target is investigational, within combination drugs, and carries that broader profile.

Children and teenagers

Glucagon has a genuine, essential pediatric use: rescuing children with diabetes from severe hypoglycemia, with the nasal product approved from age four and the analog autoinjector from age six. The needle-free nasal form is especially valuable for children, schools and caregivers. It is a vital, properly-supervised pediatric emergency medicine, the opposite of a gray-market compound.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Glucagon’s economy is a legitimate, approved one: the emergency-rescue market built around the nasal product, the autoinjector and the next-generation analog, plus the older kits, alongside procedural use and the licensing of its receptor for obesity drugs. The recent commercial story is a constructive one, ready-to-use products that improve real-world access and usability rather than marketing-driven hype.

How we got here

Glucagon was discovered in 1922 and reported in 1923 by Charles Kimball and John Murlin at the University of Rochester, who precipitated a pancreatic fraction that raised blood sugar in depancreatized dogs and rabbits and named it glucagon for its glucose-agonist action. For decades it reached patients almost exclusively as an emergency rescue kit of freeze-dried powder that a caregiver had to reconstitute with a diluent and inject, a slow and error-prone process during a hypoglycemic crisis. Modern chemistry solved that fragility with ready-to-use forms: Baqsimi as an inhaled nasal powder, Gvoke as a stable liquid in a prefilled syringe and HypoPen autoinjector, and Zegalogue built on the soluble glucagon analog dasiglucagon.

Glucagon was discovered around the same time as insulin and recognized as its counter-regulatory partner, the hormone that raises blood sugar. For decades it was supplied as emergency kits requiring reconstitution before injection. Since 2019, second-generation ready-to-use products arrived, a needle-free nasal powder, a ready-to-use autoinjector, and a stable glucagon analog, transforming how the rescue is given. In the 2020s its receptor became a target in triple-agonist obesity drugs.

  1. 1920sGlucagon is discovered alongside insulin as its counter-regulatory partner.
  2. 20th centuryIt is supplied as emergency kits requiring powder-and-liquid reconstitution.
  3. 2019 onwardReady-to-use nasal, autoinjector and analog products arrive.
  4. 2020sIts receptor becomes a target in triple-agonist obesity drugs.
  5. ongoingDual-hormone closed-loop systems are in development.

The numbers behind the grade

Type
Peptide hormone (29 aa)
Role
Raises blood glucose
Approved
Yes (rescue)
Rescue forms
Injection, nasal
New use
Weight-loss target
In
Triple agonists

The people taking it

Familiar as the emergency blood-sugar rescue hormone, and increasingly discussed as the third mechanism powering the most potent new weight-loss drugs.

Glucagon’s users are people with diabetes, especially type 1, who are at risk of severe hypoglycemia, and crucially their caregivers and families, who are the ones who actually administer it in a crisis. It is a safety net for a broad diabetes population, and also used for some gastrointestinal procedures.

Used worldwide to treat severe hypoglycemia, and its receptor is being harnessed within investigational combination drugs for obesity. A genuine approved hormone with an expanding therapeutic story.

Set against the alternatives

The defining comparison is to insulin: insulin lowers blood sugar, glucagon raises it, and together they form the diabetes-hormone pair this dossier completes. Across rescue products, the old reconstitution kits were hard to use, while the newer nasal powder, autoinjector and analog are the real advance. Against fast oral sugar or glucose tablets, which a person treats themselves with for mild lows, glucagon is for severe lows when they cannot. And against the new triple-agonist obesity drugs, glucagon’s receptor has a second life, since activating it helps the body burn energy. Its science is settled; its developments are in delivery and in new receptor uses.

What we do not know

  • How best to exploit glucagon-receptor agonism for weight loss without raising blood sugar, the balance struck by triple agonists.
  • Whether newer rescue formulations improve real-world use in hypoglycemia.

What could change

Dual-hormone systemsClosed-loop devices pairing insulin and glucagon aim to automate glucose control.Obesity drugsIts receptor is part of the newest triple-agonist weight-loss drugs.Stable formulationsWork continues on more stable, easier-to-use glucagon.AccessEfforts continue to widen rescue-product availability.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available by prescription as approved rescue products. It is a standard medical therapy, not a gray-market peptide; its weight-loss use exists only inside investigational combination drugs, not as a standalone purchase.

The rescue products carry a cost, often a few hundred dollars per device, with savings cards available and most insurance covering them. Older kits are cheaper but harder to use in an emergency.

Manufactured as an approved pharmaceutical under full regulation; a controlled, traceable supply.

Pharmaceutical makersSeveral companies supply the rescue products, from nasal powder to autoinjector to analog.Pharmacy-dispensedIt is a prescription rescue medicine kept on hand by people with diabetes.Improving usabilityReady-to-use formats are improving real-world availability and correct use.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Glucagon.

Nothing outstanding on this one.

Sources

The studies that matter

  • Established rescue usedecades

    Glucagon is the standard rescue treatment for severe hypoglycemia, available as an injection kit, an autoinjector and a nasal powder.

  • Glucagon-receptor agonism in obesity2020s

    Adding glucagon-receptor activity to GLP-1 and GIP agonism, as in the investigational triple agonist retatrutide, increases energy expenditure and fat burning, a deliberate therapeutic use of the same hormone.